Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.

Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer / M. Ferro, B. Barone, F. Crocetto, G. Lucarelli, G.M. Busetto, F. Del Giudice, M. Maggi, F. Crocerossa, F. Cantiello, R. Damiano, M. Borghesi, P.L. Bove, R. Papalia, A. Mari, S. Luzzago, F. Soria, M. Marchioni, E. La Civita, D. Terracciano, F.A. Mistretta, M. Piccinelli, A. Marmiroli, G.I. Russo, L. Schips, R. Hurle, R. Contieri, S. Perdonà, P. Del Prete, V. Mirone, O.S. Tataru, G. Musi, E. Montanari, O. de Cobelli, M.D. Vartolomei. - In: UROLOGIC ONCOLOGY. - ISSN 1873-2496. - (2022). [Epub ahead of print] [10.1016/j.urolonc.2022.05.016]

Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer

S. Luzzago;F.A. Mistretta;M. Piccinelli;A. Marmiroli;G. Musi;E. Montanari;O. de Cobelli;
2022

Abstract

Seventy-five percent of bladder cancers are non-muscle invasive. The treatment strategy includes the transurethral resection of bladder tumor (TURB) followed by intravesical immunotherapy with the bacillus of Calmette-Guerin (BCG) or chemotherapy, depending on the grade of bladder tumor. Despite a proper BCG intravesical instillations schedule, up to 40% of patients present a failure within 2 years. The aim of this retrospective study was to investigate the predictive factors in the response to BCG in patients with a high-grade non-muscle invasive bladder cancer diagnosis.
BCG; Non-muscle invasive bladder cancer; re-TURB
Settore MED/24 - Urologia
5-giu-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1078143922001867-main.pdf

solo utenti autorizzati

Tipologia: Publisher's version/PDF
Dimensione 628.75 kB
Formato Adobe PDF
628.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/931804
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact